The disclosure relates to a method of detecting the presence of tumor infiltrating Fc receptor-expressing immune cells in a mammalian subject afflicted with a cancer or detecting the presence of one or more site(s) of inflammation characterized by Fc receptor-expressing immune cells in a mammalian subject afflicted with an inflammatory disease or disorder, the method comprising administering a non-specific imaging probe comprising one or more Fc domain(s) labeled with a detectable moiety to the subject; subjecting the subject to imaging; and identifying one or more tumor(s) or sites of inflammation comprising infiltrating Fc receptor-expressing immune cells.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
The present application includes a method for preparing an alkylene oxide from an alkene that comprises reacting the alkene with ozone in the presence of a silver catalyst under conditions for selective partial oxidation of the alkene to provide the alkylene oxide at low temperatures.
C07D 301/10 - Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with air or molecular oxygen in the gaseous phase with catalysts containing silver or gold
The present application is related to a process for preparing 1-tetralone compounds such as compounds of Formula I by reacting a,|3-unsaturated cyclic ketones that comprise two available hydrogens on the y carbon to the carbonyl with acrolein derivatives with heating in the presence of a suitable organic acid, a suitable organic amine base and suitable inert solvent. For example, the 1-tetralone compound is a tetralone derivative of abscisic acid (ABA).
The present application is related to a process for preparing 1-tetralone compounds such as compounds of Formula I by reacting a,|3-unsaturated cyclic ketones that comprise two available hydrogens on the y carbon to the carbonyl with acrolein derivatives with heating in the presence of a suitable organic acid, a suitable organic amine base and suitable inert solvent. For example, the 1-tetralone compound is a tetralone derivative of abscisic acid (ABA).
C07C 51/353 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by isomerisationPreparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by change of size of the carbon skeleton
4.
METHODS AND COMPOSITIONS FOR TARGETING DISEASE RELATED CELL SURFACE RECEPTORS USING RADIOLABELED AND/OR CYTOTOXIN LABELLED ANTIBODIES
The disclosure provides radiolabeled and/or cytotoxin labelled antibodies and methods and uses of these antibodies. In one embodiment, provided is a cytotoxic agent comprising an antibody that specifically binds a target disease cell surface receptor, a cytotoxin, and a radiolabel, wherein the cytotoxin is linked directly or indirectly to the antibody, and wherein the radiolabel comprises a radionuclide and optionally a scaffold, wherein the scaffold is directly or indirectly coupled to the antibody. Also provided are methods of preparing the cytotoxic agent and methods of treating disease using the cytotoxic agent.
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
An energy exchanger is provided. The exchanger includes a housing having a front and a back. A plurality of panels forming desiccant channels extend from he front to the back of the housing. Air channels are formed between adjacent panels. The air channels are configured to direct an air stream in a direction from the front of the housing to the hack of the housing. A desiccant inlet is provided: in flow communication with the desiccant channels. A desiccant outlet is provided in flow communication with the desiccant channels. The desiccant channels are configured to channel desiccant from the desiccant inlet to the desiccant outlet in at least one of a counter-flow or cross-flow direction with respect to the direction of the air stream.
F24F 3/147 - Air-conditioning systems in which conditioned primary air is supplied from one or more central stations to distributing units in the rooms or spaces where it may receive secondary treatmentApparatus specially designed for such systems characterised by the treatment of the air otherwise than by heating and cooling by humidificationAir-conditioning systems in which conditioned primary air is supplied from one or more central stations to distributing units in the rooms or spaces where it may receive secondary treatmentApparatus specially designed for such systems characterised by the treatment of the air otherwise than by heating and cooling by dehumidification with both heat and humidity transfer between supplied and exhausted air
F24F 1/0071 - Indoor units, e.g. fan coil units with means for purifying supplied air
F24F 3/14 - Air-conditioning systems in which conditioned primary air is supplied from one or more central stations to distributing units in the rooms or spaces where it may receive secondary treatmentApparatus specially designed for such systems characterised by the treatment of the air otherwise than by heating and cooling by humidificationAir-conditioning systems in which conditioned primary air is supplied from one or more central stations to distributing units in the rooms or spaces where it may receive secondary treatmentApparatus specially designed for such systems characterised by the treatment of the air otherwise than by heating and cooling by dehumidification
F24F 12/00 - Use of energy recovery systems in air conditioning, ventilation or screening
F28D 15/00 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls
F28D 21/00 - Heat-exchange apparatus not covered by any of the groups
6.
METHODS FOR IMPROVED AIR CLASSIFICATION SEPARATION OF PULSE PROTEIN, FIBRE AND STARCHES
Described herein are methods for pre-treating pulses prior to separation of the starch and protein fractions of the pulses by air classification. Specifically, the pre-treatments weaken the structural integrity of pulse cotyledons and physically separate protein and starch inside the cotyledons, which facilitates the separation between protein and starch during subsequent milling and air classification to achieve better purity in both protein-rich and starch-rich fractions. These higher purity fractions have improved functional properties, nutritional properties, and sensory profiles, such as stronger water-holding capacity and oil-absorption capacity, emulsifying capacity and emulsion stability, and foaming properties and foam stability as well as substantially reduced beany flavor and bitter taste.
A23J 1/14 - Obtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from leguminous or other vegetable seedsObtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from press-cake or oil-bearing seeds
B02C 9/00 - Other milling methods or mills specially adapted for grain
C08B 30/02 - Preparatory treatment, e.g. crushing of raw materials
The disclosure relates to canola meal extracts (CMEs), and methods of making said CMEs. Also provided herein are compositions and culture media comprising said CMEs and use of said CMEs, compositions, and culture media for microbial fermentation across a broad class of microbes. The disclosure further relates to use of said CMEs and compositions as a partial or complete replacement for other organic extracts such as yeast extract.
Fusion polypeptides, and their use in subunit vaccine compositions to elicit immune responses against two or more pathogens are described, as well as polynucleotides encoding therefor. Also described are methods for treating and preventing infection by two or more pathogens.
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
Provided herein are methods of eliciting an immune response in one or more subject(s) against clostridium perfringens (C. perfringens) infection and/or necrotic enteritis, the method comprising administering to one or more subject(s) an amount of a composition comprising live C. perfringens and compositions for such use.
This disclosure provides a preserving composition comprising a cholesterol:carrier complex, optionally a cholesterol:cyclodextrin complex (CC complex) and/or a cell permeable antioxidant peptide and a biological buffer and optionally a cryprotectant, wherein the preserving composition is optionally substantially free of animal phospholipid, animal protein and/or animal lipoprotein. The disclosure also provides methods for the use of the preserving composition in cryopreservation of semen or sperm cells. Also provided is a kit comprising the preserving composition having a CC complex, a biological buffer, a cryoprotectant, a carbohydrate, a pH stabilizer, an antibiotic or antibiotic cocktail and/or a cell permeable anti-oxidant peptide.
Disclosed herein are cyclopolyphosphazenes of formula I:
Disclosed herein are cyclopolyphosphazenes of formula I:
Disclosed herein are cyclopolyphosphazenes of formula I:
methods for the preparation thereof and uses thereof in adjuvant compositions.
The present invention provides immunogenic chimeric respiratory syncytial virus (RSV)-parainfluenza virus type 3 (PIV3) compounds and associated compositions, along with methods of treating, preventing and/or diagnosing RSV- and PIV3-related disorders.
Provided herein is an antibody which specifically binds Muc-16 comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising complementarity determining regions CDR-L1, CDR-L2, and CDR-L3, and the heavy chain variable region comprising complementarity determining regions CDR-H1, CDR-H2, and CDR- H3, wherein the amino acid sequences of said CDRs are SEQ ID NOs: 38-43, respectively, and methods of use thereof.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure is directed to hemodialysis membranes. In particular, the present disclosure relates to hemodialysis membranes comprising uremic metabolites and zwitterionic moieties, and methods of hemodialysis thereof.
The disclosure relates to antibodies that bind human, murine, and canine IGF2R, and methods of using said antibodies. Provided herein are antibodies having specific CDRs identified herein, including functional variants of specific variable domains and IgGs having the specified CDR sequences, and immunoconjugates of said antibodies and uses thereof. Also provided herein are compositions and kits comprising said antibodies, and methods and uses of said antibodies, immunoconjugates, compositions, and kits. Also provided herein are the use of said antibodies for radioimmunotherapy (RIT) for cancer including osteosarcoma.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
The disclosure relates to methods of generating at least one brain organoid-sufficient embryoid body or repairing at least one non-viable embryoid body, the method comprising incubating a population of induced pluripotent stem cells (iPSCs) in an embryoid body formation medium (EB FM), the EB FM comprising a culture medium, glutamine, recombinant human insulin, recombinant human transferrin, sodium selenite, and thermostable fibroblast growth factor 2 (FGF2). The disclosure further relates to methods of generating brain organoids from brain organoid-sufficient embryoid bodies and repairing embryoid bodies.
The present disclosure relates to methods for reproductive management of mammalian animals using a GnRH antagonist such as Cetrorelix. Specifically, the GnRH antagonist can be used for synchronizing follicular wave emergence in a population of female mammals, and/or for fixed-time reproductive management protocols such as oocyte collection protocols, embryo collection protocols, artificial insemination protocols or embryo transfer protocols. Also described are devices and kits for reproductive management, comprising a GnRH antagonist and optionally one or more additional drugs useful for reproductive management.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61P 5/04 - Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
C07C 405/00 - Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins
A61P 5/04 - Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
The invention discloses a temperature control, optionally cooling, apparatus comprising: a first and second and/or plurality of fillable chambers each having a first layer, a second layer, an elongated edge, preferably longitudinal edge, an inlet and an outlet in the elongated, preferably longitudinal edge, and retention members between the first layer and second layer in a series of spaced veins creating a continuous channel extending from the inlet to the outlet; and a method of cooling and or maintaining an organ comprising: a method for cooling, warming and/or maintaining the temperature of an organ prior to or during a transplant procedure, the method comprising: contacting the organ with temperature control, optionally the cooling and/or temperature maintaining, apparatus; securing the apparatus to the organ; attaching the inlets of the first and second and/or plurality of fillable chambers of the apparatus to a circulation fluid source; and/or infusing circulation fluid into the inlet, through the continuous channel, and out the outlet of each of the first and second and/or plurality of fillable chambers of the apparatus.
C07C 309/14 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
The present application relates to zwitterion compounds of Formula I, to processes of their preparations, to conjugates thereof, to compositions comprising them and to their use in diagnostics and/or therapy. wherein Q is selected from Q1, Q2, Q3, Q4 and Q5:
C07C 309/14 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
Antennas, and methods of fabricating antennas, using multi-layer printed circuit boards formed via layered lamination of layers of dielectric material and metal. Metal layers contain a plurality of metal structures having a variety of lateral geometries to achieve desired antenna performance. The antennas may be discrete antennas for coupling to pre-fabricated printed circuit boards, or may be formed as integral parts of larger printed circuit boards.
The present application relates to combination treatments for breast cancer. For example, the application relates to the use of homoharringtonine and paclitaxel for the treatment of breast cancer including, for example, triple negative breast cancer.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 305/14 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
The present application relates to combination treatments for breast cancer. For example, the application relates to the use of homoharringtonine and paclitaxel for the treatment of breast cancer including, for example, triple negative breast cancer.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
C07D 305/14 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
An adaptor for a surgical clip driver is disclosed herein. The adaptor includes a first body and a second body. Each of the first body and the second body has an opening extending inwardly that is configured to receive a portion of a jaw of the surgical clip driver. The first body also includes a first body retaining member configured to retain a first portion of each of the two or more surgical clips and the second body also includes a second body retaining member configured to retain a second portion of each of the two or more surgical clips. When the first body and the second body are received on the surgical clip driver, the first body retaining member and the second body retaining member face each other and are aligned with each other to receive and retain the two or more surgical clips. A cartridge for retaining surgical clips is also disclosed herein.
The present application is related to a process for preparing 1-tetralone compounds such as compounds of Formula I by reacting a,|3-unsaturated cyclic ketones that comprise two available hydrogens on the y carbon to the carbonyl with acrolein derivatives with heating in the presence of a suitable organic acid, a suitable organic amine base and suitable inert solvent. For example, the 1-tetralone compound is a tetralone derivative of abscisic acid (ABA).
A01N 37/36 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio-analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
C07C 67/343 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisationPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by change of size of the carbon skeleton by increase in the number of carbon atoms
28.
ONE STEP SYNTHESIS OF 1-TETRALONE COMPOUNDS AND USES THEREOF IN THE PREPARATION OF (+)-TETRALONE ABSCISIC ACID (ABA)
The present application is related to a process for preparing 1-tetralone compounds such as compounds of Formula I by reacting a,|3-unsaturated cyclic ketones that comprise two available hydrogens on the y carbon to the carbonyl with acrolein derivatives with heating in the presence of a suitable organic acid, a suitable organic amine base and suitable inert solvent. For example, the 1-tetralone compound is a tetralone derivative of abscisic acid (ABA).
C07C 67/343 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisationPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by change of size of the carbon skeleton by increase in the number of carbon atoms
A01N 37/36 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio-analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
The present application includes a method for preparing an alkylene oxide from an alkene that comprises reacting the alkene with ozone in the presence of a silver catalyst under conditions for selective partial oxidation of the alkene to provide the alkylene oxide at low temperatures.
C07D 301/10 - Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with air or molecular oxygen in the gaseous phase with catalysts containing silver or gold
30.
METHOD FOR THE PREPARATION OF ALKENE OXIDES USING OZONE AT ROOM TEMPERATURE
The present application includes a method for preparing an alkylene oxide from an alkene that comprises reacting the alkene with ozone in the presence of a silver catalyst under conditions for selective partial oxidation of the alkene to provide the alkylene oxide at low temperatures.
C07D 301/10 - Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with air or molecular oxygen in the gaseous phase with catalysts containing silver or gold
31.
COMPOSITIONS AND METHODS FOR PREVENTING, CONTROLLING AND DIAGNOSING MYCOBACTERIAL INFECTIONS
Mycobacterial antigens, such as MAP and M. bovis antigens, are described. The antigens can be used in subunit compositions to elicit immune responses in order to prevent and/or control mycobacterial infections, as well as in diagnostics in order to detect mammals infected with mycobacteria.
A direct conversion x-ray detection apparatus having a planar x-ray detection layer having a detection layer upper surface and a detection layer lower surface, the planar x-ray detection layer including a lead halide perovskite material; a top electrode layer above the detection layer upper surface; a bottom electrode layer below the detection layer lower surface and in conductive communication with the top electrode layer through the x-ray detection layer to apply a bias voltage across the x-ray detection layer; and a blocking layer between the x-ray detection layer and the top electrode layer to inhibit a dark current, the blocking layer including a polymer selected from the group comprising polyacrylates, polyimides, polyamides, polysulfones, polystyrenes, and polycarbonates.
C09D 11/037 - Printing inks characterised by features other than the chemical nature of the binder characterised by the pigment
C09D 11/033 - Printing inks characterised by features other than the chemical nature of the binder characterised by the solvent
C09D 11/106 - Printing inks based on artificial resins containing macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
34.
FC DOMAIN IMAGING PROBES AND METHODS OF USE THEREOF
The disclosure relates to a method of detecting the presence of tumor infiltrating Fc receptor-expressing immune cells in a mammalian subject afflicted with a cancer or detecting the presence of one or more site(s) of inflammation characterized by Fc receptor-expressing immune cells in a mammalian subject afflicted with an inflammatory disease or disorder, the method comprising administering a non-specific imaging probe comprising one or more Fc domain(s) labeled with a detectable moiety to the subject; subjecting the subject to imaging; and identifying one or more tumor(s) or sites of inflammation comprising infiltrating Fc receptor-expressing immune cells.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The disclosure relates to a method of detecting the presence of tumor infiltrating Fc receptor-expressing immune cells in a mammalian subject afflicted with a cancer or detecting the presence of one or more site(s) of inflammation characterized by Fc receptor-expressing immune cells in a mammalian subject afflicted with an inflammatory disease or disorder, the method comprising administering a non-specific imaging probe comprising one or more Fc domain(s) labeled with a detectable moiety to the subject; subjecting the subject to imaging; and identifying one or more tumor(s) or sites of inflammation comprising infiltrating Fc receptor-expressing immune cells.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention provides immunogenic chimeric respiratory syncytial virus (RSV)- parainfluenza virus type 3 (PIV3) compounds and associated compositions, along with methods of treating, preventing and/or diagnosing RSV- and PIV3-related disorders.
The present invention provides immunogenic chimeric respiratory syncytial virus (RSV)- parainfluenza virus type 3 (PIV3) compounds and associated compositions, along with methods of treating, preventing and/or diagnosing RSV- and PIV3-related disorders.
Described herein are Staphylococcal toxins inspired peptides (STIPs) with antimicrobial activity, compositions and kits comprising the peptides, and use of the peptides to treat microbial infections. Also described are methods of inhibiting or preventing the growth of a microorganism, and methods of treating microbial infections such as bacterial infections including MRSA, and fungal infections including C. albicans.
Described herein are Staphylococcal toxins inspired peptides (STIPs) with antimicrobial activity, compositions and kits comprising the peptides, and use of the peptides to treat microbial infections. Also described are methods of inhibiting or preventing the growth of a microorganism, and methods of treating microbial infections such as bacterial infections including MRSA, and fungal infections including C. albicans.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
The disclosure relates to antibodies that bind human, murine, and canine IGF2R, and methods of using said antibodies. Provided herein are antibodies having specific CDRs identified herein, including functional variants of specific variable domains and IgGs having the specified CDR sequences, and immunoconjugates of said antibodies and uses thereof. Also provided herein are compositions and kits comprising said antibodies, and methods and uses of said antibodies, immunoconjugates, compositions, and kits. Also provided herein are the use of said antibodies for radioimmunotherapy (RIT) for cancer including osteosarcoma.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The disclosure relates to antibodies that bind human, murine, and canine IGF2R, and methods of using said antibodies. Provided herein are antibodies having specific CDRs identified herein, including functional variants of specific variable domains and IgGs having the specified CDR sequences, and immunoconjugates of said antibodies and uses thereof. Also provided herein are compositions and kits comprising said antibodies, and methods and uses of said antibodies, immunoconjugates, compositions, and kits. Also provided herein are the use of said antibodies for radioimmunotherapy (RIT) for cancer including osteosarcoma.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Systems and methods relating to estimating data symbols encoded in a received signal that has been transmitted at a faster than Nyquist rate. The present invention uses a heuristic method for non-convex problems and involves an input matrix and received samples from the received signal. These are preconditioned and the preconditioned input matrix is factorized. The method then iterates a three-step process that estimates the sequence of data symbols based on the current estimate, the preconditioned input matrix, the preconditioned samples vector, a multiplier vector, and an auxiliary vector. The process then calculates the next multiplier vector and the next auxiliary vector. If the result indicates a minimum as compared to the best estimate, then the result is used as the best estimate. Multiple iterations of the process are performed, and the multiple iterations are repeated for multiple random initializations of the estimate.
Nucleic acid molecules encoding polypeptides having polyketide synthase activity have been identified and characterized. Expression or over-expression of the nucleic acids alters levels of cannabinoid compounds in organisms. The polypeptides may be used in vivo or in vitro to produce cannabinoid compounds.
The invention discloses a temperature control, optionally cooling, apparatus comprising: a first and second and/or plurality of fillable chambers each having a first layer, a second layer, an elongated edge, preferably longitudinal edge, an inlet and an outlet in the elongated, preferably longitudinal edge, and retention members between the first layer and second layer in a series of spaced veins creating a continuous channel extending from the inlet to the outlet; and a method of cooling and or maintaining an organ comprising: a method for cooling, warming and/or maintaining the temperature of an organ prior to or during a transplant procedure, the method comprising: contacting the organ with temperature control, optionally the cooling and/or temperature maintaining, apparatus; securing the apparatus to the organ; attaching the inlets of the first and second and/or plurality of fillable chambers of the apparatus to a circulation fluid source; and/or infusing circulation fluid into the inlet, through the continuous channel, and out the outlet of each of the first and second and/or plurality of fillable chambers of the apparatus.
B65D 81/18 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
49.
APPARATUS AND METHODS FOR CONTROLLING ORGAN TEMPERATURE PRIOR TO AND/OR DURING TRANSPLANTATION PROCEDURES
The invention discloses a temperature control, optionally cooling, apparatus comprising: a first and second and/or plurality of fillable chambers each having a first layer, a second layer, an elongated edge, preferably longitudinal edge, an inlet and an outlet in the elongated, preferably longitudinal edge, and retention members between the first layer and second layer in a series of spaced veins creating a continuous channel extending from the inlet to the outlet; and a method of cooling and or maintaining an organ comprising: a method for cooling, warming and/or maintaining the temperature of an organ prior to or during a transplant procedure, the method comprising: contacting the organ with temperature control, optionally the cooling and/or temperature maintaining, apparatus; securing the apparatus to the organ; attaching the inlets of the first and second and/or plurality of fillable chambers of the apparatus to a circulation fluid source; and/or infusing circulation fluid into the inlet, through the continuous channel, and out the outlet of each of the first and second and/or plurality of fillable chambers of the apparatus.
B65D 81/18 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
An adaptor for a surgical clip driver is disclosed herein. The adaptor includes a first body and a second body. Each of the first body and the second body has an opening extending inwardly that is configured to receive a portion of a jaw of the surgical clip driver. The first body also includes a first body retaining member configured to retain a first portion of each of the two or more surgical clips and the second body also includes a second body retaining member configured to retain a second portion of each of the two or more surgical clips. When the first body and the second body are received on the surgical clip driver, the first body retaining member and the second body retaining member face each other and are aligned with each other to receive and retain the two or more surgical clips. A cartridge for retaining surgical clips is also disclosed herein.
A61B 17/128 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord for applying or removing clamps or clips
51.
ADDITIVES FOR PROMOTING IMPERMEABILITY IN FIBER PRODUCTS
The present application relates to additives for fiber products for promoting oil and water impermeability. Additives or blend of additives for fiber products are provided. The additive comprises at least one modified starch or the blend comprises at least one modified starch, in combination with at least one sizing agent and/or at least one cationic polymer. A composition for fiber products comprising fiber materials; water; and the blend of additives is also provided, uses and methods thereof. The biodegradable and compostable additives of the present application may be used as substitutes for per- and polyfluoroalkyl substances (PFASs) to impart grease and water impermeability in fiber products.
The present application relates to novel 3′-unsaturated abscisic acid (ABA) derivatives of Formula (I) as ABA antagonists. For example, the present application relates to methods of using compounds of Formula (I) for reducing adverse effects of an ABA response in plants such as lentil and promoting germination. (I) The present application also relates to methods of using 3′-phenyl abscisic acid (ABA) derivatives of Formula (II) as ABA antagonists, for example, for reducing adverse effects of an ABA response in plants such as lentil and promoting germination. (II)
C07C 59/90 - Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
A01N 37/42 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing within the same carbon skeleton a carboxylic group or a thio-analogue, or a derivative thereof, and a carbon atom having only two bonds to hetero atoms with at the most one bond to halogen, e.g. keto-carboxylic acids
Provided herein are cytosine-phosphate-guanine (CpG) recoded oncolytic flaviviruses having silent mutations which increase frequency of CpG dinucleotide instances within the viral genome as compared to wild-type, and methods and uses thereof for the treatment of cancer, such as brain cancer, and particularly glioblastomas such as SOX2-negative glioblastoma. Pharmaceutical compositions and kits are also provided, as well as glioblastoma stem cell-derived tumor models, methods for the production thereof, and methods and uses thereof for identifying anti-cancer agents targeting glioblastoma.
The present application relates to a method of producing protein products comprising extracting water soluble protein extracts from pulse or hemp, and de-flavouring the water soluble protein extract using suitable non-polar resins. Further, the present application relates to the protein products produced using the methods of the present application and uses thereof. The present application also relates to food and/or health products formulated with the protein products.
A23J 1/14 - Obtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from leguminous or other vegetable seedsObtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from press-cake or oil-bearing seeds
Mycobacterial antigens, such as MAP and M. bovis antigens, are described. The antigens can be used in subunit compositions to elicit immune responses in order to prevent and/or control mycobacterial infections, as well as in diagnostics in order to detect mammals infected with mycobacteria.
M. bovisM. bovis antigens, are described. The antigens can be used in subunit compositions to elicit immune responses in order to prevent and/or control mycobacterial infections, as well as in diagnostics in order to detect mammals infected with mycobacteria.
A direct conversion x-ray detection apparatus having a planar x-ray detection layer having a detection layer upper surface and a detection layer lower surface, the planar x-ray detection layer including a lead halide perovskite material; a top electrode layer above the detection layer upper surface; a bottom electrode layer below the detection layer lower surface and in conductive communication with the top electrode layer through the x-ray detection layer to apply a bias voltage across the x-ray detection layer; and a blocking layer between the x-ray detection layer and the top electrode layer to inhibit a dark current, the blocking layer including a polymer selected from the group comprising polyacrylates, polyimides, polyamides, polysulfones, polystyrenes, and polycarbonates.
C09D 11/03 - Printing inks characterised by features other than the chemical nature of the binder
C09D 11/106 - Printing inks based on artificial resins containing macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
C09D 11/38 - Inkjet printing inks characterised by non-macromolecular additives other than solvents, pigments or dyes
C09D 139/06 - Homopolymers or copolymers of N-vinyl-pyrrolidones
G01T 1/24 - Measuring radiation intensity with semiconductor detectors
H01L 31/115 - Devices sensitive to very short wavelength, e.g. X-rays, gamma-rays or corpuscular radiation
H10K 30/60 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation in which radiation controls flow of current through the devices, e.g. photoresistors
A direct conversion x-ray detection apparatus having a planar x-ray detection layer having a detection layer upper surface and a detection layer lower surface, the planar x-ray detection layer including a lead halide perovskite material; a top electrode layer above the detection layer upper surface; a bottom electrode layer below the detection layer lower surface and in conductive communication with the top electrode layer through the x-ray detection layer to apply a bias voltage across the x-ray detection layer; and a blocking layer between the x-ray detection layer and the top electrode layer to inhibit a dark current, the blocking layer including a polymer selected from the group comprising polyacrylates, polyimides, polyamides, polysulfones, polystyrenes, and polycarbonates.
C09D 11/037 - Printing inks characterised by features other than the chemical nature of the binder characterised by the pigment
C09D 11/106 - Printing inks based on artificial resins containing macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
Methods and compositions for enhancing an immune response, such as a mucosal immune response, to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites.
C07K 14/30 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
C12N 15/62 - DNA sequences coding for fusion proteins
61.
Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies
The disclosure provides radiolabeled and/or cytotoxin labelled antibodies and methods and uses of these antibodies. In one embodiment, provided is a cytotoxic agent comprising an antibody that specifically binds a target disease cell surface receptor, a cytotoxin, and a radiolabel, wherein the cytotoxin is linked directly or indirectly to the antibody, and wherein the radiolabel comprises a radionuclide and optionally a scaffold, wherein the scaffold is directly or indirectly coupled to the antibody. Also provided are methods of preparing the cytotoxic agent and methods of treating disease using the cytotoxic agent.
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
62.
METHODS AND COMPOSITIONS FOR TARGETING DISEASE RELATED CELL SURFACE RECEPTORS USING RADIOLABELED AND/OR CYTOTOXIN LABELLED ANTIBODIES
C07H 15/24 - Condensed ring systems having three or more rings
C07H 15/252 - Naphthacene radicals, e.g. daunomycins, adriamycins
C07K 5/027 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link in which at least a gamma-amino acid is involved, e.g. statine
C07K 7/64 - Cyclic peptides containing only normal peptide links
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present application relates to a method of increasing the volume of an airway surface liquid (ASL) layer and/or increasing mucociliary clearance in a subject. For example, the application relates the use of one or more neuronal agonists such as menthol and/or capsaicin, in combination with hypertonic saline (HTS) or isotonic saline (ITS) for increasing the volume of airway surface liquid (ASL) and/or increasing mucociliary clearance or for treatment of a disease, disorder or condition treatable by increasing the volume of an ASL layer and/or increasing mucociliary clearance. For example, the disease, disorder or condition is cystic fibrosis or a non-cystic fibrosis respiratory disease, disorder or condition such as non-cystic fibrosis bronchiectasis.
ABSTRACTThe present application relates to a method of increasing the volume of an airway surface liquid (ASL) layer in a subject. For example, the application relates the use of one or more neuronal agonists such as menthol and/or capsaicin, in combination with hypertonic saline (HTS) for increasing the volume of airway surface liquid (ASL) or for treatment of a disease, disorder or condition treatable by increasing the volume of an ASL layer. For example, the disease is a respiratory disease including cystic fibrosis and non-cystic fibrosis bronchiectasis.- 59 -3694654CA 3069390 2020-01-23
Novel airway devices and methods address complications of ventilating a patient with a mask; placing an endotracheal tube in an awake patient; and need for a bite block during flexible bronchoscopy and gastroscopy. The airway device features notches for engaging maxillary and mandibular teeth in a manner protracting the patient's mandible relative to the maxilla to open up the airway. This way, an open airway is easily maintained simply by holding the jaw closed against the device with the same hand used to operate a bag ventilator. A longitudinal channel in the device features a downwardly curved end wall for improved guidance of the endoscope into position. The channel is open sided at the top or bottom to allow rolling of the airway device off the endoscope into an offset position serving as a protective bite block and allowing feeding of the endotracheal tube along the endoscope.
A61B 1/24 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the mouth, i.e. stomatoscopes, e.g. with tongue depressorsInstruments for opening or keeping open the mouth
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
A61B 1/273 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the upper alimentary canal, e.g. oesophagoscopes, gastroscopes
Methods and uses of activators of the APC complex for treating cancer in a subject, inhibiting the growth of a cancer cell, increasing sensitivity to a cancer treatment in a cancer cell or a subject and/or reducing resistance to a cancer treatment in a cancer cell or a subject.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
This disclosure provides a preserving composition comprising a cholesterol: carrier complex, optionally a cholesterol:cyclodextrin complex (CC complex) and/or a cell permeable antioxidant peptide and a biological buffer and optionally a cryprotectant, wherein the preserving composition is optionally substantially free of animal phospholipid, animal protein and/or animal lipoprotein. The disclosure also provides methods for the use of the preserving composition in cryopreservation of semen or sperm cells. Also provided is a kit comprising the preserving composition having a CC complex, a biological buffer, a cryoprotectant, a carbohydrate, a pH stabilizer, an antibiotic or antibiotic cocktail and/or a cell permeable anti-oxidant peptide.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Described are methods and uses employing metabolomic data to diagnose an asthma disease state or a Chronic Obstructive Pulmonary Disease (COPD) state. Further described are methods of uses of employing metabolomic data to distinguish between asthma and COPD. In particular, urinary metabolomic profiles are employed to enable differential diagnosis of asthma and COPD.
G01N 33/493 - Physical analysis of biological material of liquid biological material urine
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61B 5/08 - Measuring devices for evaluating the respiratory organs
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
82.
Genes and proteins for aromatic polyketide synthesis
Nucleic acid molecules encoding polypeptides having polyketide synthase activity have been identified and characterized. Expression or over-expression of the nucleic acids alters levels of cannabinoid compounds in organisms. The polypeptides may be used in vivo or in vitro to produce cannabinoid compounds.
L intracellularis antigens for use in subunit vaccine compositions to elicit immune responses against L intracellularis infections such as proliferative enteropathy (PE) are described, as well as polynucleotides encoding therefor. Also described are methods for treating and preventing L intracellularis infections.
Methods of detecting pipeline weakening are described herein. The methods include creating a pressure wave in a fluid flowing in a pipeline using an input transducer located at a first position along the pipeline; measuring the pressure wave using an output transducer positioned at a second position along the pipeline that is spaced from the first position, and generating an output signal based on the pressure wave; analyzing the output signal to determine a stiffness of a sidewall of the pipeline positioned between the input transducer and output transducer; and determining if the sidewall includes a defect based on the stiffness of the sidewall, including analyzing a frequency response of the output signal to detect the defect.
G01N 3/30 - Investigating strength properties of solid materials by application of mechanical stress by applying a single impulsive force
F17D 5/06 - Preventing, monitoring, or locating loss using electric or acoustic means
G01M 3/24 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using infrasonic, sonic, or ultrasonic vibrations
G01M 5/00 - Investigating the elasticity of structures, e.g. deflection of bridges or aircraft wings
G01N 29/07 - Analysing solids by measuring propagation velocity or propagation time of acoustic waves
G01N 29/12 - Analysing solids by measuring frequency or resonance of acoustic waves
G01M 3/36 - Investigating fluid tightness of structures by using fluid or vacuum by detecting change in dimensions of the structure being tested
G01N 3/20 - Investigating strength properties of solid materials by application of mechanical stress by applying steady bending forces
The disclosure is directed to antibodies and binding fragments thereof that specifically bind HER3. The disclosure is further directed to immunoconjugates comprising the antibodies and binding fragments thereof that specifically bind HER3. The disclosure is also directed to uses of the antibodies, binding fragments thereof and immunoconjugates for detecting HER3-expressing cells and for treating HER3-expressing cancer.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 9/00 - Medicinal preparations characterised by special physical form
The present application relates to novel 3'-unsaturated abscisic acid (ABA) derivatives of Formula (I) as ABA antagonists. For example, the present application relates to methods of using compounds of Formula (I) for reducing adverse effects of an ABA response in plants such as lentil and promoting germination. (I) The present application also relates to methods of using 3'-phenyl abscisic acid (ABA) derivatives of Formula (II) as ABA antagonists, for example, for reducing adverse effects of an ABA response in plants such as lentil and promoting germination. (II)
A01N 37/42 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing within the same carbon skeleton a carboxylic group or a thio-analogue, or a derivative thereof, and a carbon atom having only two bonds to hetero atoms with at the most one bond to halogen, e.g. keto-carboxylic acids
C07C 59/90 - Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
89.
Methods and compositions for inducing protective immunity
This application relates to compositions comprising one or more CpG oligodeoxynucleotides complexed to nanoparticles comprising a gemini surfactant and optionally a muco-adhesive polymer, which can be used for intrapulmonary delivery to induce immunity in feed animals, and the methods of making and uses thereof.
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A23K 20/153 - Nucleic acidsHydrolysis products or derivatives thereof
A23K 50/75 - Feeding-stuffs specially adapted for particular animals for birds for poultry
C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 39/00 - Medicinal preparations containing antigens or antibodies
90.
3'-UNSATURATED ABSCISIC ACID DERIVATIVES AS ABA ANTAGONISTS
The present application relates to novel 3'-unsaturated abscisic acid (ABA) derivatives of Formula (I) as ABA antagonists. For example, the present application relates to methods of using compounds of Formula (I) for reducing adverse effects of an ABA response in plants such as lentil and promoting germination. (I) The present application also relates to methods of using 3'-phenyl abscisic acid (ABA) derivatives of Formula (II) as ABA antagonists, for example, for reducing adverse effects of an ABA response in plants such as lentil and promoting germination. (II)
C07C 59/90 - Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
A01N 37/42 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing within the same carbon skeleton a carboxylic group or a thio-analogue, or a derivative thereof, and a carbon atom having only two bonds to hetero atoms with at the most one bond to halogen, e.g. keto-carboxylic acids
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
A method is described for treating plant seed samples with dilute acid solution followed by a drying step to removed unwanted compounds from the seed sample. Unwanted compounds that can be removed from samples using the method include cyanogenic glycosides glucosinolates, alkaloidal amines, and cadmium. Samples are treated in dilute acid (from about 0 75% to about 4 % acetic acid, lactic acid or H2CO3) for up to 48 hrs, followed by drying of the acid treated sample.
Methods and compositions for enhancing an immune response, such as a mucosal immune response, to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Methods and compositions for enhancing an immune response, such as a mucosal immune response, to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites.
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
The Governing Council of the University of Toronto (Canada)
Inventor
Sidhu, Sachdev
Miersch, Shane
Geyer, Clarence Ronald
Abstract
An Epidermal Growth Factor Receptor (EGFR, HER1, ErbB1)-binding agent has a heavy chain and a light chain, wherein the dimerization loop from EGFR's Domain II is grafted within complementarity determining region 3 (CDR3) of the heavy chain, and the binding agent is affinity matured. The graft directs the binding agent to bind EGFR at its dimerization region, to thereby inhibit EGFR dimerization and activation. In another embodiment, an EGFR-binding agent is panned out of Library F, a Fab library. The binding agents are for detecting and/or quantifying EGFR expression, for targeting EGFR-expressing cells, and for decreasing levels of EGFR in EGFR-expressing cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
